Benny. I agree with your recent posts except I see the SVB failure as more of a canary in a coal mine warning vs your tempest in a teapot view. Financing requirements , terms for biotechs wanting to raise cash to fund clinical trials etc ...will now be more restrictive. Office buildings that are only at 50-70% occupancy are likely to default on their loans.
None of this is likely to be a concern for AUPH since they have a sizable cash on hand . Their challenge is to increase script numbers and get at least to breakeven .
News 
Market Data 
Discover 
AI
